Evidence map›Paper›PMID 35337361›Full record

ReviewMolecular cancer2022

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.

Hui Zhou, Liyong Zhu, Jun Song, Guohui Wang, Pengzhou Li, Weizheng Li, Ping Luo, Xulong Sun, Jin Wu, Yunze Liu and 2 more

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 165 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 1 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06001528 recruitingnot on this map

Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer

TypeobservationalSponsorShantou Central HospitalRan2021 to 2026Enrolled2,400ConditionsBreast Cancer, Lymph Node Metastasis
NCT06654622 completednot on this mapstarted 2023, after this paper: background citation

An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer

Typeobservational_patient_registrySponsorCity of Hope Medical CenterRan2023 to 2026Enrolled175ConditionsColo-rectal Cancer, Colorectal Cancer Recurrent
3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.

  1. Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hui Zhou *Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Liyong Zhu *Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Jun Song *Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Guohui WangDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Pengzhou LiDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Weizheng LiDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Ping LuoDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Xulong SunDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Jin WuDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Yunze LiuDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Shaihong ZhuDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China. shzhu@mail.csu.edu.cn.
Yi ZhangDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. drcsuzhy@gmail.com.
Central South University · CNXuzhou Medical College · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by the operator for clinical decisions. Because conventional tissue biopsy is invasive and only a small sample can sometimes be obtained, it is unable to represent the heterogeneity of tumor or dynamically monitor tumor progression. Therefore, there is an urgent need to find a new minimally invasive or noninvasive diagnostic strategy to detect CRC at an early stage and monitor CRC recurrence. Over the past years, a new diagnostic concept called "liquid biopsy" has gained much attention. Liquid biopsy is noninvasive, allowing repeated analysis and real-time monitoring of tumor recurrence, metastasis or therapeutic responses. With the advanced development of new molecular techniques in CRC, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and tumor-educated platelet (TEP) detection have achieved interesting and inspiring results as the most prominent liquid biopsy markers. In this review, we focused on some clinical applications of CTCs, ctDNA, exosomes and TEPs and discuss promising future applications to solve unmet clinical needs in CRC patients.

Indexed as

Circulating Tumor DNAColorectal NeoplasmsNeoplastic Cells, CirculatingBiomarkers, TumorHumansLiquid BiopsyNeoplasm Recurrence, LocalPrognosisBiomarkers, TumorCirculating Tumor DNACirculating tumor cellsCirculating tumor DNAClinical applicationColorectal cancerExosomesLiquid biopsyTumor-educated platelets

Identifiers

PMID35337361
PMCPMC8951719
OpenAlexW4220665248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.